Abstract
Obesity-associated hyperlipidemia and hyperlipoproteinemia are risk factors for cardiovascular disease (CVD). Recently, sphingomiolin (SM), a ceramide-derived sphingolipid, was identified as a new independent risk factor of CVD. We hypothesize that the effect of gastric bypass (RYGB) on reduced cardiovascular risk is related to ceramide-mediated improvement in lipoprotein profile.
Full Text
Published Version
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call